Li’s group blocked the interaction between PARP-2 and FOXA1 by targeting PARP-2 with the selective PARP-2 inhibitor UPF-1069, thereby attenuating AR-mediated gene expression and inhibiting AR-positive PCa growth [149]. The gene discussed is AR; the disease is posterior cortical atrophy.